These studies suggested that a reduction in the genesis of EVs containing the oxidized mtDNA represents a possible therapeutic strategy for mitigating the risk of ALD-associated HCC in ALDH2-deficient individuals 39. This evidence concerns the gene ALDH2 and hepatocellular carcinoma.